Simon Barry J. sold $269K of IBRX
Simon Barry J. sold 25,000 shares of ImmunityBio, Inc. (IBRX) at $10.75 ($0.27M total) on 2026-10-05 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed sale is modest relative to total holdings, suggesting limited immediate price impact.
Market read
A routine insider sale with modest size; likely low relevance for short‑term traders but useful for monitoring insider activity.
What to watch
Potential upcoming clinical trial milestones or FDA interactions not mentioned could offset the sell pressure.
Background
SEC Form 4 filings disclose insider transactions; a 10b5-1 plan indicates pre‑arranged sales, often used to avoid timing concerns.
Ticker impact
Director Simon Barry J. sold 25,000 shares for $268,760 via a 10b5-1 plan, reducing his stake to 2,777,788 shares.
likely slight pressure as the market prices in the insider sell
Form 4 filings are primary source, but the transaction size (< $1M) is modest, limiting market impact.
Market effects
Minimal effect on the broader biotech sector; typical insider sales are routine.
US market only; no regional ripple.
Low; limited to investors tracking ImmunityBio.
Counterpoint
The sale could be unrelated to company fundamentals; investors may view it as a routine liquidity move.
Key entities
- CompanyImmunityBio, Inc.
Biotech firm developing immunotherapies, ticker IBRX.
- IndividualSimon Barry J.
Director of ImmunityBio executing a pre‑arranged stock sale.
